前列腺素E_1治疗肢体动脉硬化性闭塞症的临床疗效  

Clinical observation on effects of prostaglandin E_1 infusion in patients with arteriosclerosis obliterans

作　　者：赵长林[1] 陈璘[1] 刘金来[1] 易敏慈 梁真[1] 

机构地区：[1]中山医科大学附属第三医院心内科,广州510630

出　　处：《中国临床药学杂志》2000年第5期279-288,共10页Chinese Journal of Clinical Pharmacy

摘　　要：目的 :探讨前列腺素 E1 (PGE1 )治疗肢体动脉硬化性闭塞症 (ASO)的临床疗效和安全性。方法 :36例 ASO患者给予PGE1 治疗 ,10 0︼g/ d,iv gtt,疗程 14d,观察治疗前后患者症状、无痛性行走距离、踝臂压力比率、患肢胫后动脉平均血液流速的变化以及不良反应。结果 :86 .1%患者自觉症状改善或明显改善 ;无痛性行走距离由 (2 48.1± 78.2 ) m延长至 (336 .2±86 .4) m;踝臂压力比率由 0 .6 1± 0 .32增至 0 .90± 0 .43;患肢胫后动脉平均血液流速也由 (2 .1± 1.1)上升至 (3.5± 1.1) cm/s。除了注射部位疼痛外 ,其他不良反应较少见。结论 :PGE1 对AIM: To study the effects and safety of prostaglandin E 1 (PGE 1) infusion on arteriosclerosis obliterans (ASO). METHODS: Thirty six patients with ASO were treated with PGE 1 infusion for 14 d. The changes of symptoms, pain free walking distance, ankle brachial pressure ratio, average calf blood flow velocity were observed. RESULTS: The symptoms of 86 1% patients with ASO had improvement. Pain free walking distance was increased from (248 1±78 2) m to (336 2±86 4) m. There was also an increase in the ankle brachial pressure ratio (from 0 61±0 32 to 0 90±0 43). And the average calf blood flow velocity was increased from (2 1±1 1) to (3 5±1 1) cm/s. Side effects of PGE 1 infusion were slight. CONCLUSION: The PGE 1 is an effective and safe drug for the treatment of the patients with ASO.

关 键 词：肢体动脉硬化性闭塞症 前列腺素E1 药物治疗 

分 类 号：R96[医药卫生—药理学]